| Year |
Citation |
Score |
| 2023 |
Janganati V, Salazar P, Parks BJ, Gorman GS, Prather PL, Peterson EC, Alund AW, Moran JH, Crooks PA, Brents LK. Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats. Frontiers in Pharmacology. 14: 1123261. PMID 37229250 DOI: 10.3389/fphar.2023.1123261 |
0.695 |
|
| 2020 |
Brents LK, Kulbeth HJ. Automated Quantification of Opioid Withdrawal Severity in Neonatal Rat Pups Using Ethovision® XT Software The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.04811 |
0.31 |
|
| 2019 |
Griffin BA, Caperton CO, Russell LN, Cabalong CV, Wilson CD, Urquhart KR, Martins BS, Zita MD, Patton AL, Alund AW, Owens SM, Fantegrossi WE, Moran JH, Brents LK. exposure to norbuprenorphine, a major metabolite of buprenorphine, induces fetal opioid dependence and leads to neonatal opioid withdrawal syndrome. The Journal of Pharmacology and Experimental Therapeutics. PMID 31028107 DOI: 10.1124/Jpet.118.254219 |
0.645 |
|
| 2018 |
Brents L, Griffin BA, Caperton C, Russell L, Cabanlong C, Wilson C, Urquhart K, Martins B, Patton AL, Alund AW, Owens SM, Fantegrossi WE, Moran JH. 2421 Development and validation of a translational rat model of neonatal abstinence syndrome Journal of Clinical and Translational Science. 2: 9-9. DOI: 10.1017/cts.2018.63 |
0.577 |
|
| 2015 |
Tai S, Hyatt WS, Gu C, Franks LN, Vasiljevik T, Brents LK, Prather PL, Fantegrossi WE. Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. Pharmacological Research. 102: 22-32. PMID 26361728 DOI: 10.1016/J.Phrs.2015.09.006 |
0.738 |
|
| 2014 |
Marshell R, Kearney-Ramos T, Brents LK, Hyatt WS, Tai S, Prather PL, Fantegrossi WE. In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection. Pharmacology, Biochemistry, and Behavior. 124: 40-7. PMID 24857780 DOI: 10.1016/J.Pbb.2014.05.010 |
0.749 |
|
| 2014 |
Brents LK, Prather PL. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metabolism Reviews. 46: 72-85. PMID 24063277 DOI: 10.3109/03602532.2013.839700 |
0.686 |
|
| 2013 |
Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE. Differential drug-drug interactions of the synthetic cannabinoids JWH-018 and JWH-073: Implications for drug abuse liability and pain therapys Journal of Pharmacology and Experimental Therapeutics. 346: 350-361. PMID 23801678 DOI: 10.1124/Jpet.113.206003 |
0.76 |
|
| 2013 |
Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicology and Applied Pharmacology. 269: 100-8. PMID 23537664 DOI: 10.1016/J.Taap.2013.03.012 |
0.749 |
|
| 2013 |
Madadi NR, Penthala NR, Brents LK, Ford BM, Prather PL, Crooks PA. Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors. Bioorganic & Medicinal Chemistry Letters. 23: 2019-21. PMID 23466226 DOI: 10.1016/J.Bmcl.2013.02.025 |
0.677 |
|
| 2012 |
Koryakina Y, Jones SM, Cornett LE, Seely K, Brents L, Prather PL, Kofman A, Kurten RC. Effects of the β-agonist, isoprenaline, on the down-regulation, functional responsiveness and trafficking of β2-adrenergic receptors with N-terminal polymorphisms. Cell Biology International. 36: 1171-83. PMID 22938397 DOI: 10.1042/Cbi20120134 |
0.736 |
|
| 2012 |
Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 2174-84. PMID 22904561 DOI: 10.1124/Dmd.112.047530 |
0.792 |
|
| 2012 |
Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies Neuropharmacology. 63: 905-915. PMID 22771770 DOI: 10.1016/J.Neuropharm.2012.06.046 |
0.679 |
|
| 2012 |
Safe SH, Prather PL, Brents LK, Chadalapaka G, Jutooru I. Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs. Anti-Cancer Agents in Medicinal Chemistry. 12: 1211-20. PMID 22583404 DOI: 10.2174/187152012803833099 |
0.634 |
|
| 2012 |
Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, Prather PL, Safe S. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Molecular Cancer Therapeutics. 11: 1421-31. PMID 22553354 DOI: 10.1158/1535-7163.Mct-12-0026 |
0.605 |
|
| 2012 |
Seely KA, Brents LK, Radominska-Pandya A, Endres GW, Keyes GS, Moran JH, Prather PL. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chemical Research in Toxicology. 25: 825-7. PMID 22404317 DOI: 10.1021/Tx3000472 |
0.796 |
|
| 2012 |
Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity Biochemical Pharmacology. 83: 952-961. PMID 22266354 DOI: 10.1016/J.Bcp.2012.01.004 |
0.765 |
|
| 2012 |
Brents LK, Medina-Bolivar F, Seely KA, Nair V, Bratton SM, Nopo-Olazabal L, Patel RY, Liu H, Doerksen RJ, Prather PL, Radominska-Pandya A. Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 42: 139-56. PMID 21970716 DOI: 10.3109/00498254.2011.609570 |
0.787 |
|
| 2011 |
Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase i hydroxylated metabolites of the k2 synthetic cannabinoid jwh-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity Plos One. 6. PMID 21755008 DOI: 10.1371/Journal.Pone.0021917 |
0.789 |
|
| Show low-probability matches. |